We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+24.59%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.9B
AUM Growth
+$12.2B
Cap. Flow
+$2B
Cap. Flow %
3.34%
Top 10 Hldgs %
21.63%
Holding
3,213
New
281
Increased
1,628
Reduced
1,147
Closed
147

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$134M
2
MSFT icon
Microsoft
MSFT
+$119M
3
AAPL icon
Apple
AAPL
+$87.6M
4
ABBV icon
AbbVie
ABBV
+$61.7M
5
META icon
Meta Platforms (Facebook)
META
+$54.9M

Sector Composition

Rank Sector Weight
1 Technology 23.43%
2 Healthcare 14.28%
3 Financials 13.11%
4 Consumer Discretionary 10.94%
5 Communication Services 9.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OESX icon
2976
Orion Energy Systems
OESX
$71.9M
$77K ﹤0.01%
+2,216
New +$90.7K
PTRS
2977
DELISTED
Partners Bancorp Common Stock
PTRS
$76K ﹤0.01%
+11,520
New +$80.3K
ING icon
2978
ING
ING
$102B
$75K ﹤0.01%
+10,927
New +$66.3K
TEF
2979
DELISTED
Telefonica
TEF
$75K ﹤0.01%
18,478
+2,584
+16% +$10K
PSEC icon
2980
Prospect Capital
PSEC
$1.11B
$73K ﹤0.01%
14,347
+58
+0.4% +$271
SNFCA icon
2981
Security National Financial
SNFCA
$251M
$73K ﹤0.01%
+14,866
New +$64.3K
SLNO
2982
DELISTED
Soleno Therapeutics
SLNO
$72K ﹤0.01%
+2,166
New +$93.9K
BXG
2983
DELISTED
Bluegreen Vacations Corporation Common Stock
BXG
$72K ﹤0.01%
13,324
-1,320
-9% -$6.29K
CEMI
2984
DELISTED
Chembio diagnostics, Inc.
CEMI
$72K ﹤0.01%
+22,203
New +$211K
IMDX
2985
Insight Molecular Diagnostics
IMDX
$155M
$71K ﹤0.01%
1,855
+963
+108% +$49.7K
CFRX
2986
DELISTED
ContraFect Corporation
CFRX
$71K ﹤0.01%
+139
New +$68.2K
AVEO
2987
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$69K ﹤0.01%
+13,328
New +$84.1K
NEXT icon
2988
NextDecade
NEXT
$1.81B
$68K ﹤0.01%
31,400
+14,995
+91% +$27.4K
FLNA
2989
Filana Therapeutics
FLNA
$46.3M
$68K ﹤0.01%
+22,023
New +$99.9K
TH icon
2990
Target Hospitality
TH
$1.59B
$66K ﹤0.01%
39,009
+4,070
+12% +$7.89K
ACH
2991
DELISTED
Alum Corp of China Ltd
ACH
$66K ﹤0.01%
+14,038
New +$70K
NL icon
2992
NLI Holdings
NL
$308M
$65K ﹤0.01%
19,109
+5,559
+41% +$17.2K
CKPT
2993
DELISTED
Checkpoint Therapeutics
CKPT
$64K ﹤0.01%
3,239
+1,538
+90% +$28K
ELA icon
2994
Envela
ELA
$468M
$64K ﹤0.01%
+10,555
New +$38.6K
ETON icon
2995
Eton Pharmaceutcials
ETON
$1.26B
$63K ﹤0.01%
+11,630
New +$57.8K
MRKR icon
2996
Marker Therapeutics
MRKR
$18.7M
$63K ﹤0.01%
3,065
+852
+38% +$18.6K
CTOS icon
2997
Custom Truck One Source
CTOS
$2.52B
$62K ﹤0.01%
+15,480
New +$45K
ORGO icon
2998
Organogenesis Holdings
ORGO
$310M
$61K ﹤0.01%
+15,823
New +$57.1K
PAVM icon
2999
PAVmed
PAVM
$35.4M
$61K ﹤0.01%
+64
New +$64K
AVTX icon
3000
Avalo Therapeutics
AVTX
$1B
$60K ﹤0.01%
8
+2
+33% +$14.5K

Similar funds

RhumbLine Advisers's Q2 2020 Portfolio in Review

As of Q2 2020, RhumbLine Advisers held 3,213 positions worth $59.9B, up 25% from $47.7B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

RhumbLine Advisers deployed $2B of net new capital in Q2 2020, opening 281 new positions and adding to 1,628 existing holdings. Its largest new stake was Otis Worldwide: 701,378 shares worth $39.9M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was iShares Core S&P Mid-Cap ETF, an estimated $12.9M trimmed.

  • RhumbLine Advisers's largest Q2 2020 buy was Otis Worldwide: 701,378 shares worth $39.9M.
  • RhumbLine Advisers added most to Amazon in Q2 2020, an estimated $134M increase.
  • RhumbLine Advisers's biggest Q2 2020 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $12.9M.
  • RhumbLine Advisers fully exited Allergan plc in Q2 2020, selling an estimated $92.9M.
  • RhumbLine Advisers's ten largest holdings make up 22% of its $59.9B portfolio in Q2 2020.
  • RhumbLine Advisers opened 281 new positions and closed 147 in Q2 2020.
  • RhumbLine Advisers's portfolio value rose 25% quarter-over-quarter to $59.9B.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.